PAVmed Inc. — fact timeline

PAVmed Inc. reported financial results for year ended December 31, 2025.

“PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results”

PAVmed Inc. reported three months ended December 31, 2025 results: net income approximately $1.8 million, EPS $(2.05) per common share on a diluted basis.

“For the three months ended December 31, 2025, Operating expenses were approximately $6.9 million which include stock-based compensation expenses of $0.3 million. GAAP net loss attributable to common stockholders was approximately $1.8 million, or $(2.05) per common share on a diluted basis.”

PAVmed Inc.: Approved amendment to certificate of incorporation to permit removal of directors with or without cause by majority vote (effective 2026-03-27).

“A certificate of amendment reflecting the amendment to the Certificate of Incorporation was filed with the Delaware Secretary of State on March 27, 2026 and became effective on such date.”

PAVmed Inc. amended Amended and Restated 2022 Note (the "2026 Note") with the Holder valued at $15 million principal amount (effective 2026-02-03).

“Concurrently with the Offering, the Company redeemed all 16,962 shares of Series C Preferred Stock outstanding and refinanced all $8,414,890 in principal and interest of its Senior Secured Convertible Note issued in September (the “ 2022 Note ”), in consideration of a cash payment to the holder thereof (the “ Holder ”) of approximately $22,346,241 (which was made using proceeds from the sale of the Series D Preferred Stock), and the issuance to the Holder of an amended and restated 2022 Note (the “ 2026 Note ”) with a principal amount of $15 million.”

PAVmed Inc. entered into Subscription Agreements with certain accredited investors valued at $30 million aggregate purchase price (effective 2026-02-03).

“On February 3, 2026, PAVmed Inc. (the “ Company ”) entered into subscription agreements (the “ Subscription Agreements ”) with certain accredited investors (the “ Investors ”) and, pursuant to and concurrently with the execution of the Subscription Agreements, sold to the Investors, for an aggregate purchase price of $30 million, (i) 30,000 shares of the Company’s newly designated Series D Convertible Preferred Stock, par value $0.001 per share (the “ Series D Preferred Stock ”), and (ii) warrants (the “ Warrant ”) to purchase an additional 30,000 shares of Series D Preferred Stock, with each investor receiving 100 shares of Series D Preferred Stock and a warrant to purchase 100 shares of Series D Preferred Stock for each $100,000 of its investment (the “ Offering ”).”

PAVmed Inc.: Certificate of amendment to effect a 1-for-30 reverse stock split and reduce authorized common stock from 250,000,000 to 25,000,000 shares (effective 2026-01-02).

“the Company filed a certificate of amendment to its certificate of incorporation, as amended, pursuant to which the Reverse Split and the Reduction in Authorized Common Stock will become effective on Friday, January 2, 2026, at 12:01 a.m. Eastern Time”

PAVmed Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 23, 2025, PAVmed Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that, for the prior 30 consecutive business days (through J”

Sundeep Agrawal, M.D. was appointed as Class B Director at PAVmed Inc..

“the Company’s board of directors appointed Sundeep Agrawal, M.D. as a Class B director.”

Joan B. Harvey resigned as Director at PAVmed Inc..

“James L. Cox, M.D., and Joan B. Harvey resigned from the Company’s board of directors.”

James L. Cox, M.D. resigned as Director at PAVmed Inc..

“James L. Cox, M.D., and Joan B. Harvey resigned from the Company’s board of directors.”

PAVmed Inc. reported three months ended March 31, 2024 results: revenue $1.0 million, net income $22.8 million, EPS $(2.62) per common share.

“well in furtherance of this revised strategy.” Highlights from the first quarter and recent weeks include : ● Yesterday, Lucid reported that 1Q24 EsoGuard ® revenue was $1.0 million, which was flat compared to 4Q23 and represents a 124 percent increase from 1Q23. ● Strengthened balance sheet by Lucid’s completion of a $29.8 million Series B Preferred Stock”

PAVmed Inc. entered into Subscription Agreement with certain accredited investors valued at approximately $11.6 million (effective 2024-05-01).

“entered into subscription agreements (each, a “ Subscription Agreement ”) with certain accredited investors (collectively, the “ Investors ”), which agreements provided for the sale to the Investors of approximately 11,634 shares of Lucid Diagnostics’ newly designated Series B-1 Convertible Preferred Stock, par value $0.001 per share (the “ Series B-1 Preferred Stock ”), at a purchase price of $1,000 per share (collectively, the “ Offering ”). The gross proceeds to Lucid Diagnostics of the Offering were approximately $11.6 million.”

PAVmed Inc. entered into Registration Rights Agreement with Series B Investors (effective 2024-03-13).

“Lucid Diagnostics and the Series B Investors also executed a registration rights agreement (the “ Registration Rights Agreement ”), pursuant to which the Company agreed to file a registration statement covering the resale of the shares of Common Stock issuable pursuant to the Series B Preferred Stock.”

PAVmed Inc. entered into Exchange Agreement with certain accredited investors valued at 13,625 shares of Lucid Diagnostics’ Series A Convertible Preferred Stock, par value $0.001 per share (effective 2024-03-13).

“On March 13, 2024, Lucid Diagnostics Inc. (the “ Lucid Diagnostics ”), a majority owned subsidiary of PAVmed Inc. (the “ Company ”), entered into subscription agreements (each, a “ Series B Subscription Agreement ”) and exchange agreements (each, an “ Exchange Agreement ”) with certain accredited investors (collectively, the “ Series B Investors ”), which agreements provided for (i) the sale to the Series B Investors of 12,495 shares of Lucid Diagnostics’ newly designated Series B Convertible Preferred Stock, par value $0.001 per share (the “ Series B Preferred Stock ”), at a purchase price of $1,000 per share, and (ii) the exchange by the Series B Investors of 13,625 shares of Lucid Diagnostics’ Series A Convertible Preferred Stock, par value $0.001 per share (the “ Series A Preferred Stock ”), and 10,670 shares of Lucid Diagnostics’ Series A-1 Convertible Preferred Stock, par value $0.001 per share (the “ Series A-1 Preferred Stock ”), held by them for 31,790 shares of Series B Prefe”

PAVmed Inc. entered into Series B Subscription Agreement with certain accredited investors valued at 12,495 shares of Lucid Diagnostics’ newly designated Series B Convertible Preferred Stock, par value (effective 2024-03-13).

“On March 13, 2024, Lucid Diagnostics Inc. (the “ Lucid Diagnostics ”), a majority owned subsidiary of PAVmed Inc. (the “ Company ”), entered into subscription agreements (each, a “ Series B Subscription Agreement ”) and exchange agreements (each, an “ Exchange Agreement ”) with certain accredited investors (collectively, the “ Series B Investors ”), which agreements provided for (i) the sale to the Series B Investors of 12,495 shares of Lucid Diagnostics’ newly designated Series B Convertible Preferred Stock, par value $0.001 per share (the “ Series B Preferred Stock ”), at a purchase price of $1,000 per share”

PAVmed Inc. amended Amendment and Waiver with holder of senior secured convertible notes valued at $2,000,000 cash payment; maturity extended to April 4, 2025 (April 2022 Note) and September 8, 2025 (effective 2024-03-12).

“Effective as of March 12, 2024, PAVmed Inc. (the “ Company ”), entered into an amendment and waiver (the “ Amendment and Waiver ”) with the holder of the senior secured convertible note issued by the Company as of April 4, 2022 (the “ April 2022 Note ”) and the secured convertible note issued by the Company as of September 8, 2022 (the “ September 2022 Note ,” and together with the April 2022 Note, the “ Notes ”).”